KEY TAKEAWAYS
- The observational study aimed to investigate the effectiveness of olaparib maintenance therapy in advanced ovarian cancer pts.
- The primary objective was to determine the PFS rate.
- Researchers noticed a significant advancement by establishing olaparib as a safe and effective 1L treatment for BRCA ovarian cancer pts; further information will be provided later.
Olaparib has proven efficacious as a maintenance therapy in newly diagnosed advanced ovarian cancer among women with BRCA mutations. However, its effectiveness in those without BRCA mutations is not well-established.
Jing Li and his team aimed to assess the therapeutic potential of olaparib in a broader population of ovarian cancer patients (pts).
The study performed an inclusive analysis utilizing real-world data obtained from eleven high-volume tertiary care centers in China. A retrospective cohort study design was employed to assess the efficacy and safety of olaparib maintenance therapy in the first-line (1L) setting for BRCA wild-type ovarian cancer pts. Eligible women were identified through meticulous medical record review at each participating institution. The primary objective centered on determining the 1-year progression-free survival (PFS) rate, concurrently evaluating the safety profile details.
About 50 patients, with a median age of 54 years, were included in the study. Among them, 44 patients (88%) were diagnosed with International Federation of Gynaecology and Obstetrics (FIGO) stage III disease, while 6 patients (12%) had stage IV disease at diagnosis. The study observed a 1-year progression-free survival (PFS) rate of 75.2% (95% CI, 63.4 to 89.2), with a median PFS of 21.0 months (95% CI, 13.8 to 28.2). All patients received olaparib at an initial dose of 300 mg twice daily, and no serious adverse events (AEs) were reported. Dose adjustments were made for 8 patients (16%), but no patients discontinued olaparib treatment due to AEs.
The study concluded that establishing the inaugural evidence that olaparib emerges as a safe and effective 1L maintenance treatment for women diagnosed with BRCA wild-type ovarian cancer. These findings suggest a promising new treatment option for this significant patient subgroup.
The study is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Clinical Trial: https://clinicaltrials.gov/study/NCT05153603
Li J, Youguo C, Mian H, et al. (2023). “First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study.” Presented at ESMO ASIA 2023 (Abstract 316 P).
